In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate
- PMID: 16607616
- DOI: 10.1002/ana.20836
In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate
Abstract
Objective: Spinal muscular atrophy results from loss of the survival motor neuron 1 (SMN1) gene and malfunction of the remaining SMN2. We investigated whether valproic acid can elevate human SMN expression in vivo.
Methods: Blood was collected from 10 spinal muscular atrophy carriers and 20 spinal muscular atrophy patients treated with valproic acid.
Results: Seven of 10 carriers demonstrated increased SMN messenger RNA and protein levels. SMN2 messenger RNA levels were elevated in 7 patients and unchanged or decreased in 13 patients.
Interpretation: We provide first proof of the in vivo activation of a causative gene by valproic acid in an inherited disease and discuss strategies of monitoring drug response in patients.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
